HighTide Therapeutics, a biotech developing drugs for metabolic and digestive diseases in both the US and China, is seeking to raise around $36 million (HK$278 million) from an IPO in Hong Kong.
HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for approval in China within two to three years.
HighTide Therapeutics and Quotient Sciences Announce Agreement to Conduct a 14C Human ADME Program for HTD1801
ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced that two abstracts related to its HTD1801 development program will be presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Washington, DC (November 4 – 8, 2022).
ROCKVILLE, Md. & SHENZHEN, China--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Daniel Ripley as Senior Vice President of Business Development.
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company developing drugs with multi-functional biological actions to address the complex pathophysiology of metabolic and digestive diseases, announced that the first patient was dosed in a phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus (T2DM) in China.
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a global, clinical-stage biopharmaceutical company leading the discovery and development of multi-functional drugs with synergistic effects to treat metabolic and digestive diseases, today announced the appointment of Myleen Leoncavallo as Senior Vice President of Regulatory Affairs and Quality Assurance.
SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing treatments for chronic liver / gastrointestinal diseases and metabolic disorders, today announced that the company and U.S. Food and Drug Administration (FDA) reached agreement to proceed to Phase 3 development of HTD1801 for the treatment of primary sclerosing cholangitis (PSC). The company had a productive discussion with FDA as part of an End-of-Phase 2 meeting, regarding the key elements of the study design and will be submitting a Phase 3 protocol to FDA for review and comment.